Executive Assistant

Blockonomi 1 day ago 129 Tldr. * ARGX slips 1.00% as blockbuster VYVGART sales reach $1.7 billion in Q3 2026. * Argenx profit climbs to $506 million, but ARGX shares still face selling pressure. * VYVGART sales jump 54% year over year as Argenx expands its treatment pipeline. * Rising development costs push Argenx quarterly operating expenses to $1.27B. * December empasiprubart results could mark Argenx's next major clinical milestone. Argenx SE (ARGX) shares fell despite stronger third-quarter sales and higher profit. The stock declined 1.00% to $881.15, losing $8.90 during trading. Shares recovered from early lows before renewed selling emerged near $890 during a volatile session. argenx SE, ARGX VYVGART drives strong quarterly sales. Argenx reported $1.72 billion in third-quarter product sales, up 54% from last year. Sales rose 13% sequentially as demand grew across major treatment areas. The company markets VYVGART for autoimmune conditions, including generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy. Total operating income reached $1.75 billion, against $1.15 billion one year earlier. Quarterly operating profit rose to $486 million from $346 million in the comparable period. Net profit increased to $506 million from $344 million, while basic earnings reached $8.07 per share. Nine-month VYVGART sales totaled $4.53 billion versus $2.87 billion a year earlier. Operating profit doubled to $1.37 billion, reflecting stronger commercial activity over nine months. However, the company increased spending to support development, marketing, and operations. Rising expenses offset part of growth. Third-quarter operating expenses climbed to $1.27 billion from $805 million a year earlier. Research and development costs increased to $503 million as argenx advanced clinical programs across multiple diseases. Selling, general and administrative expenses reached $598 million, compared with $336 million last year. Administrative spending included approximately $150 million in costs related to the Forte Biosciences acquisition. Argenx paid about $2.1 billion for that transaction, net of acquired cash. Combined cash and current financial assets totaled $3.7 billion in September, down from $4.4 billion in December. Argenx now expects combined research, development, and administrative expenses near $4 billion for 2026. That estimate includes Forte acquisition costs and ongoing commercial expansion. The updated forecast reflects spending on its pipeline alongside VYVGART sales growth worldwide. Drug pipeline sets up coming milestones. Argenx submitted an FDA application to expand VYVGART treatment into ocular myasthenia gravis. The FDA also granted priority review for pediatric generalized myasthenia gravis, targeting February 2027. Additionally, argenx expects a VYVGART Hytrulo autoinjector launch during the second half of 2027. Positive Phase 3 ALKIVIA results supported further development in immune-mediated muscle diseases. Argenx expects an application for immune-mediated necrotizing myopathy before year-end 2026. Meanwhile, its empasiprubart Phase 3 study in multifocal motor neuropathy should report results in December. The company plans Phase 3 development for FB102 in celiac disease following promising earlier results. Its Vision 2030 targets 50,000 treated patients, 10 approved indications, and five candidates in registrational development. Despite sales growth and clinical progress, ARGX shares faced continued selling pressure. The post Argenx SE (ARGX) stock: falls despite $1.7 billion sales and profit growth appeared first on blockonomi. BitRss shares this Content always with License. Screenshot generated in real time with SneakPeek Suite * homepage * flash news * Argenx SE (ARGX) stock: falls despite $1.7 billion sales and profit growth.

Argenx SE (ARGX) stock: falls despite $1.7 billion sales and profit growth. Stronger VYVGART sales and earnings fail to lift ARGX as expenses rise and drug trials advance. Tldr. Table of Contents * ARGX slips 1.00% as blockbuster VYVGART sales reach $1.7 billion in Q3 2026. * Argenx profit climbs to $506 million, but ARGX shares still face selling pressure. * VYVGART sales jump 54% year over year as Argenx expands its treatment pipeline. * Rising development costs push Argenx quarterly operating expenses to $1.27B. * December empasiprubart results could mark Argenx's next major clinical milestone. Argenx SE (ARGX) shares fell despite stronger third-quarter sales and higher profit. The stock declined 1.00% to $881.15, losing $8.90 during trading. Shares recovered from early lows before renewed selling emerged near $890 during a volatile session. VYVGART drives strong quarterly sales. Argenx reported $1.72 billion in third-quarter product sales, up 54% from last year. Sales rose 13% sequentially as demand grew across major treatment areas. The company markets VYVGART for autoimmune conditions, including generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy. Total operating income reached $1.75 billion, against $1.15 billion one year earlier. Quarterly operating profit rose to $486 million from $346 million in the comparable period. Net profit increased to $506 million from $344 million, while basic earnings reached $8.07 per share. Nine-month VYVGART sales totaled $4.53 billion versus $2.87 billion a year earlier. Operating profit doubled to $1.37 billion, reflecting stronger commercial activity over nine months. However, the company increased spending to support development, marketing, and operations. Rising expenses offset part of growth. Third-quarter operating expenses climbed to $1.27 billion from $805 million a year earlier. Research and development costs increased to $503 million as argenx advanced clinical programs across multiple diseases. Selling, general and administrative expenses reached $598 million, compared with $336 million last year. Administrative spending included approximately $150 million in costs related to the Forte Biosciences acquisition. Argenx paid about $2.1 billion for that transaction, net of acquired cash. Combined cash and current financial assets totaled $3.7 billion in September, down from $4.4 billion in December. Argenx now expects combined research, development, and administrative expenses near $4 billion for 2026. That estimate includes Forte acquisition costs and ongoing commercial expansion. The updated forecast reflects spending on its pipeline alongside VYVGART sales growth worldwide. Drug pipeline sets up coming milestones. Argenx submitted an FDA application to expand VYVGART treatment into ocular myasthenia gravis. The FDA also granted priority review for pediatric generalized myasthenia gravis, targeting February 2027. Additionally, argenx expects a VYVGART Hytrulo autoinjector launch during the second half of 2027. Positive Phase 3 ALKIVIA results supported further development in immune-mediated muscle diseases. Argenx expects an application for immune-mediated necrotizing myopathy before year-end 2026. Meanwhile, its empasiprubart Phase 3 study in multifocal motor neuropathy should report results in December. The company plans Phase 3 development for FB102 in celiac disease following promising earlier results. Its Vision 2030 targets 50,000 treated patients, 10 approved indications, and five candidates in registrational development. Despite sales growth and clinical progress, ARGX shares faced continued selling pressure. Limited Time Offer Get 3 free stock ebooks. Discover top-performing stocks in AI, Crypto, and Technology with expert analysis. * Top 10 AI Stocks - Leading AI companies * Top 10 Crypto Stocks - Blockchain leaders * Top 10 Tech Stocks - Tech giants

argenx reported third-quarter product net sales of $1.7 billion, up 54% from a year earlier and 13% from the previous quarter. Demand for its drug VYVGART kept growing in generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy. Operating profit was $486 million, a 28% margin, or 37% excluding $150 million in costs from the Forte acquisition. The company ended the quarter with $3.7 billion in cash and current financial assets after paying a net $2.1 billion for Forte. argenx plans to file for VYVGART approval in immune-mediated necrotizing myopathy by year-end. It could have up to five US launches in 2027. It expects combined research and development and selling, general and administrative expenses of about $4 billion for 2026, and is moving Forte's FB-102 into Phase III for celiac disease.